{"id":984838,"date":"2026-07-27T07:09:05","date_gmt":"2026-07-27T11:09:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/"},"modified":"2026-07-27T07:09:05","modified_gmt":"2026-07-27T11:09:05","slug":"okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/","title":{"rendered":"OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>LONDON and NEW YORK, July  27, 2026  (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (Nasdaq:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YM70CZLH_mxcl5x4kqwVwKZEOYSjlDsf354vJizA4oNSFzjikH884vFwDxlzlfXeWt7fz0NgS1mVooEC5qAtqD7Y3-zpFvbKWBVTR8xhfqdjo54MPgchmcikY6e2xXMt\" rel=\"nofollow\" target=\"_blank\">OKYO<\/a>), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.<\/p>\n<p>\n        <strong>Company Participation<\/strong>: Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli MD, PhD, Chief Medical Officer<\/p>\n<p>\n        <strong>Date\/Time: <\/strong>July 28-29, 2026<\/p>\n<p>\n        <strong>Location:<\/strong> Virtual<\/p>\n<p>\n        <strong>1:1 Meetings<\/strong>: schedule a one-on-one meeting with management by contacting your BTIG representative<\/p>\n<p>\n        <strong>About OKYO<\/strong><br \/>\n        <strong>Pharma<\/strong><br \/>\n        <br \/>OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.<\/p>\n<p>For further information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Oo1y_eeaPaGsZEVBrml-ufAnq6PDoWEL3GNxIyNlhXI0Il6aCJy6XZenfbkwzfKrokCkgSneGvn-__jCIEJkAZEQsfJ-oTwAZMoQGncCW5w=\" rel=\"nofollow\" target=\"_blank\">www.okyopharma.com<\/a>.<\/p>\n<p>\n        <strong>For further inquiries:<\/strong>\n      <\/p>\n<p>\n        <strong>OKYO Pharma Ltd<\/strong><br \/>\n        <br \/>Paul Spencer<br \/>Business Development and Investor Relations<br \/>+44 (0) 207 495 2379<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ytl0_z9PTmhcSlAKyCcXW3IuoQVf6RDm-cCN7m2KLp_lVdh-v4vPK1O3dBouoy0fFv_tangHFGU7scAQKMbfnmEGQd8_kt0tuq0cfkYqDS8=\" rel=\"nofollow\" target=\"_blank\">info@okyopharma.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzcwMyM3NzIxOTI1IzIyMDE0NDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTYwZmFjNWUtNWM4Mi00YzlkLWI4ZDEtNGQ2ZDcyMDc3NDU2LTEyMTI5OTYtMjAyNi0wNy0yNy1lbg==\/tiny\/OKYO-Pharma-LTD.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (Nasdaq:\u00a0OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026. Company Participation: Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli MD, PhD, Chief Medical Officer Date\/Time: July 28-29, 2026 Location: Virtual 1:1 Meetings: schedule a one-on-one meeting with management by contacting your BTIG representative About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-984838","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (Nasdaq:\u00a0OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026. Company Participation: Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli MD, PhD, Chief Medical Officer Date\/Time: July 28-29, 2026 Location: Virtual 1:1 Meetings: schedule a one-on-one meeting with management by contacting your BTIG representative About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with &hellip; Continue reading &quot;OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-27T11:09:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzcwMyM3NzIxOTI1IzIyMDE0NDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026\",\"datePublished\":\"2026-07-27T11:09:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/\"},\"wordCount\":191,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NzcwMyM3NzIxOTI1IzIyMDE0NDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/\",\"name\":\"OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NzcwMyM3NzIxOTI1IzIyMDE0NDM=\",\"datePublished\":\"2026-07-27T11:09:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NzcwMyM3NzIxOTI1IzIyMDE0NDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2NzcwMyM3NzIxOTI1IzIyMDE0NDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/","og_locale":"en_US","og_type":"article","og_title":"OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 - Market Newsdesk","og_description":"LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) &#8212; OKYO Pharma Limited (Nasdaq:\u00a0OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026. Company Participation: Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli MD, PhD, Chief Medical Officer Date\/Time: July 28-29, 2026 Location: Virtual 1:1 Meetings: schedule a one-on-one meeting with management by contacting your BTIG representative About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with &hellip; Continue reading \"OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-27T11:09:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzcwMyM3NzIxOTI1IzIyMDE0NDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026","datePublished":"2026-07-27T11:09:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/"},"wordCount":191,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzcwMyM3NzIxOTI1IzIyMDE0NDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/","name":"OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzcwMyM3NzIxOTI1IzIyMDE0NDM=","datePublished":"2026-07-27T11:09:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzcwMyM3NzIxOTI1IzIyMDE0NDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2NzcwMyM3NzIxOTI1IzIyMDE0NDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/984838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=984838"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/984838\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=984838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=984838"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=984838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}